Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:NVO News 10 December 2025 - 5 February 2026

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk forecast 2026 adjusted sales and operating profit will fall 5%–13% at constant exchange rates, citing pricing pressure and competition. U.S.-listed shares dropped about 12% after the outlook. The company reported 2025 sales up 10% to 309.1 billion Danish crowns and operating profit up 6%. Early U.S. uptake of its Wegovy pill was noted, but patent expiries and lower realized prices remain concerns.
3 February 2026
·
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B shares closed up 1.17% at 401.35 crowns in Copenhagen, lifted by strong early U.S. demand for its new Wegovy pill. The company faces a new U.S. lawsuit alleging a “pay-for-delay” scheme for Victoza. Over 18,000 Wegovy pill prescriptions were reported in the U.S. since its Jan. 5 launch. Indian regulators approved local firms to make generic semaglutide ahead of the 2026 patent expiry.
24 January 2026
··
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly shares closed Friday at $1,038.40, up 0.5% after trading between $1,019 and $1,049.83. Investors are watching for FDA decisions on Lilly’s obesity pill and tracking early prescription data as Novo Nordisk’s Wegovy pill posts strong initial sales. U.S. markets will be closed Monday, reopening Tuesday. Lilly’s next earnings call is scheduled for February 4.
18 January 2026
··
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon shares rose 0.4% after hours to $247.33 following news that Amazon Pharmacy will offer Novo Nordisk’s Wegovy weight-loss pill at $25 per month for insured customers and $149 for cash-pay. The pill, approved by the FDA in December, will be shipped to all 50 states. Investors await Amazon’s Q4 results on Feb. 5 and a key EU digital proposal on Jan. 20.
9 January 2026
····
Novo Nordisk stock slips premarket as China court backs key semaglutide patent

Novo Nordisk stock slips premarket as China court backs key semaglutide patent

NEW YORK, January 2, 2026, 05:42 ET — Premarket Novo Nordisk A/S shares edged lower in premarket trading on Friday after the Danish drugmaker said China’s Supreme People’s Court upheld a key patent covering semaglutide, the active ingredient in its blockbuster obesity and diabetes drugs. U.S.-listed American depositary receipts (ADRs) — certificates that represent foreign shares — were down about 0.7% at $50.88. The ruling matters because semaglutide underpins Wegovy for obesity and Ozempic and Rybelsus for type 2 diabetes, products that have driven Novo’s growth and investor attention. Patent protection on the molecule can help slow copycat competition in
2 January 2026
·
Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

December 25, 2025 — U.S. markets are closed for Christmas, but healthcare stocks are ending the year with a burst of sector-defining catalysts: a landmark oral GLP‑1 approval for weight loss, multiple FDA green lights that moved biotech names sharply, and a renewed M&A drumbeat as big pharma and rare-disease specialists shop for growth. Below is a detailed, news-driven roundup of the most important healthcare stock headlines, forecasts, and analyst themes investors are digesting as of Dec. 25, 2025—and what they could mean for pharma stocks, biotech stocks, medtech stocks, and health insurance stocks in early 2026. Why healthcare stocks
25 December 2025
·
Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk A/S – the Danish maker of Ozempic and Wegovy – is having the kind of year investors usually wake up from, not live through. On 11 December 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) trade around $49 per share, after a bounce of roughly 5–6% in recent sessions. Copenhagen-listed B‑shares sit near 316 DKK, yet they remain close to 50% lower than where they started 2025, putting the stock on track for its worst year on record.MarketBeat+2MarketScreener+2 A new wave of research notes and news out today sharpen the picture: 2026 is now expected to be a year
11 December 2025
··
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk stock is having a very noisy December 10, 2025. American depositary shares of Novo Nordisk A/S (ticker NVO) recently traded around $48 in New York, up roughly 3–4% intraday, with the session range hovering between about $47 and $48.3. That rebound comes after months of brutal underperformance and a barrage of fresh news: an M&A deal closing, obesity pipeline updates, an important downgrade from Argus, and increasingly loud questions about whether the GLP‑1 champion can hold its crown. This is exactly the kind of setup that confuses the daylights out of investors: bullish long‑term story, ugly short‑term chart,
10 December 2025
··

Stock Market Today

Strategy (MSTR) stock price whipsaws after $12.4 billion loss as bitcoin steadies — what to watch next week

Strategy (MSTR) stock price whipsaws after $12.4 billion loss as bitcoin steadies — what to watch next week

7 February 2026
New York, Feb 7, 2026, 08:53 EST — Market closed. Strategy Inc (MSTR) shares jumped 26.1% on Friday to close at $134.93, a sharp rebound after the stock sank 17.1% on Thursday to $106.99. (StockAnalysis) The move matters because the former MicroStrategy has become a listed proxy for bitcoin. When crypto turns, the stock tends to turn harder. Bitcoin was last around $68,933 on Saturday, up about 2.4% from the prior close, leaving traders to guess whether this is a bounce or just breathing room. Strategy said it swung to a fourth-quarter net loss of $12.4 billion, or $42.93 per
American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

American Airlines stock jumps nearly 8% as airlines rally — what to watch next week

7 February 2026
American Airlines shares jumped 7.6% to $15.24 Friday, rebounding with a broad rally that sent the Dow past 50,000 for the first time. Investors are watching the carrier’s battle with United at Chicago O’Hare, where a summer capacity surge could trigger a fare war. American also announced new Philadelphia–Porto service for 2027 and launched a centennial inflight menu.
Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

Apple stock price ends week higher as Dow hits 50,000; jobs and CPI loom next

7 February 2026
Apple closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. The S&P 500 jumped 1.97% and the Nasdaq rose 2.18% as chipmakers rallied, while Amazon fell 5.6% on higher capex guidance. Investors await U.S. jobs data Feb. 11 and CPI Feb. 13. Apple’s next dividend is $0.26 per share, payable Feb. 12.
Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
Go toTop